Accelerated cognitive decline and hippocampal volume loss in mild cognitive impaired carriers of Apolipoprotein‐E ε4

The ε4 allele of the Apolipoprotein‐E (APOE) gene is the major genetic risk factor for late‐onset Alzheimer’s disease (AD). APOE ε4 carriers represent around 45% of AD population, with each copy of APOE ε4 allele conferring increased risk for AD. Here, we aim to quantify disease progression during the early clinical stage of AD using imaging biomarkers to stratify patient populations for therapeutic interventions.